Do analysts prefer GRI or ASBP?

GRI Bio presently has a consensus price target of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Aspire Biopharma. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Aspire Biopharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRI or ASBP more profitable?

Aspire Biopharma's return on equity of 0.00% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% Aspire Biopharma N/A N/A -398.04%

Do analysts rate GRI or QNRX?

GRI Bio currently has a consensus target price of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's higher possible upside, analysts clearly believe GRI Bio is more favorable than Quoin Pharmaceuticals. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Quoin Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, GRI or QNRX?

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$74.16 N/A Quoin Pharmaceuticals N/A N/A -$15.81M -$29.56 N/A

Is GRI or QNRX more profitable?

GRI Bio's return on equity of -199.52% beat Quoin Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% Quoin Pharmaceuticals N/A -489.85% -221.29%

Does the media favor GRI or QNRX?

In the previous week, GRI Bio and GRI Bio both had 1 articles in the media. GRI Bio's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GRI Bio 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Quoin Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, GRI or CNSP?

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$74.16 N/A CNS Pharmaceuticals N/A N/A -$15.85M -$29.63 N/A

Is GRI or CNSP more profitable?

GRI Bio's return on equity of -199.52% beat CNS Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% CNS Pharmaceuticals N/A -238.68% -166.30%

Do analysts prefer GRI or OBSV?

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than ObsEva. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GRI Bio 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 ObsEva 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has better valuation & earnings, GRI or OBSV?

GRI Bio is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio GRI Bio N/A N/A -$11.96M -$74.16 N/A ObsEva N/A N/A -$58.38M -$0.92 N/A

Is GRI or OBSV more profitable?

GRI Bio's return on equity of -199.52% beat ObsEva's return on equity. Company Net Margins Return on Equity Return on Assets GRI Bio N/A -199.52% -143.23% ObsEva N/A -416.36% -92.01%

Is LEXX or GRI more profitable?

Lexaria Bioscience's return on equity of -174.93% beat GRI Bio's return on equity. Company Net Margins Return on Equity Return on Assets Lexaria Bioscience N/A -174.93% -143.89% GRI Bio N/A -199.52% -143.23%

GRI Bio (GRI) Competitors

$1.70 +0.23 (+15.65%)

Closing price 08/10/2026 04:00 PM Eastern

Extended Trading

$1.80 +0.10 (+5.59%)

As of 08:27 AM Eastern

Compare

GRI vs. ASBP, QNRX, CNSP, OBSV, and LEXX

Should you buy GRI Bio stock or one of its competitors? GRI Bio's main competitors and comparable companies include Aspire Biopharma (ASBP), Quoin Pharmaceuticals (QNRX), CNS Pharmaceuticals (CNSP), ObsEva (OBSV), and Lexaria Bioscience (LEXX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does GRI Bio compare to Aspire Biopharma?

GRI Bio (NASDAQ:GRI) and Aspire Biopharma (NASDAQ:ASBP) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, earnings, valuation, media sentiment, analyst recommendations, institutional ownership, profitability and dividends.

GRI Bio has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market. Comparatively, Aspire Biopharma has a beta of 0.11, indicating that its share price is 89% less volatile than the broader market.

GRI Bio presently has a consensus price target of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than Aspire Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Aspire Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 19.2% of Aspire Biopharma shares are held by institutional investors. 8.7% of GRI Bio shares are held by company insiders. Comparatively, 5.8% of Aspire Biopharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, GRI Bio had 1 more articles in the media than Aspire Biopharma. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for Aspire Biopharma. Aspire Biopharma's average media sentiment score of 0.56 beat GRI Bio's score of 0.00 indicating that Aspire Biopharma is being referred to more favorably in the news media.

Company	Overall Sentiment
GRI Bio	Neutral
Aspire Biopharma	Positive

Aspire Biopharma's return on equity of 0.00% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
Aspire Biopharma	N/A	N/A	-398.04%

GRI Bio has higher earnings, but lower revenue than Aspire Biopharma. Aspire Biopharma is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
Aspire Biopharma	$10K	1,012.70	-$24.48M	-$116.67	N/A

Summary

GRI Bio beats Aspire Biopharma on 10 of the 14 factors compared between the two stocks.

How does GRI Bio compare to Quoin Pharmaceuticals?

GRI Bio (NASDAQ:GRI) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.

Quoin Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
Quoin Pharmaceuticals	N/A	N/A	-$15.81M	-$29.56	N/A

GRI Bio has a beta of -1.2, meaning that its share price is 220% less volatile than the broader market. Comparatively, Quoin Pharmaceuticals has a beta of 1.49, meaning that its share price is 49% more volatile than the broader market.

GRI Bio currently has a consensus target price of $32.00, suggesting a potential upside of 1,782.35%. Given GRI Bio's higher possible upside, analysts clearly believe GRI Bio is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Quoin Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

GRI Bio's return on equity of -199.52% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
Quoin Pharmaceuticals	N/A	-489.85%	-221.29%

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by company insiders. Comparatively, 11.2% of Quoin Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

In the previous week, GRI Bio and GRI Bio both had 1 articles in the media. GRI Bio's average media sentiment score of 0.00 equaled Quoin Pharmaceuticals'average media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
GRI Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Quoin Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

GRI Bio beats Quoin Pharmaceuticals on 6 of the 9 factors compared between the two stocks.

How does GRI Bio compare to CNS Pharmaceuticals?

GRI Bio (NASDAQ:GRI) and CNS Pharmaceuticals (NASDAQ:CNSP) are both small-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, dividends, institutional ownership, analyst recommendations, earnings and profitability.

GRI Bio has a beta of -1.2, indicating that its share price is 220% less volatile than the broader market. Comparatively, CNS Pharmaceuticals has a beta of 3.05, indicating that its share price is 205% more volatile than the broader market.

In the previous week, GRI Bio had 1 more articles in the media than CNS Pharmaceuticals. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for CNS Pharmaceuticals. GRI Bio's average media sentiment score of 0.00 equaled CNS Pharmaceuticals'average media sentiment score.

Company	Overall Sentiment
GRI Bio	Neutral
CNS Pharmaceuticals	Neutral

34.0% of GRI Bio shares are owned by institutional investors. Comparatively, 14.0% of CNS Pharmaceuticals shares are owned by institutional investors. 8.7% of GRI Bio shares are owned by insiders. Comparatively, 0.0% of CNS Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

GRI Bio's return on equity of -199.52% beat CNS Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
CNS Pharmaceuticals	N/A	-238.68%	-166.30%

CNS Pharmaceuticals is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
CNS Pharmaceuticals	N/A	N/A	-$15.85M	-$29.63	N/A

GRI Bio presently has a consensus price target of $32.00, suggesting a potential upside of 1,782.35%. CNS Pharmaceuticals has a consensus price target of $20.00, suggesting a potential upside of 289.86%. Given GRI Bio's higher possible upside, analysts clearly believe GRI Bio is more favorable than CNS Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
CNS Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

GRI Bio beats CNS Pharmaceuticals on 8 of the 10 factors compared between the two stocks.

How does GRI Bio compare to ObsEva?

GRI Bio (NASDAQ:GRI) and ObsEva (NASDAQ:OBSV) are both small-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their valuation, risk, dividends, analyst recommendations, profitability, institutional ownership, media sentiment and earnings.

34.0% of GRI Bio shares are held by institutional investors. Comparatively, 17.5% of ObsEva shares are held by institutional investors. 8.7% of GRI Bio shares are held by insiders. Comparatively, 14.4% of ObsEva shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, GRI Bio had 1 more articles in the media than ObsEva. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for ObsEva. GRI Bio's average media sentiment score of 0.00 equaled ObsEva'saverage media sentiment score.

Company	Overall Sentiment
GRI Bio	Neutral
ObsEva	Neutral

GRI Bio is trading at a lower price-to-earnings ratio than ObsEva, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A
ObsEva	N/A	N/A	-$58.38M	-$0.92	N/A

GRI Bio's return on equity of -199.52% beat ObsEva's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
GRI Bio	N/A	-199.52%	-143.23%
ObsEva	N/A	-416.36%	-92.01%

GRI Bio currently has a consensus target price of $32.00, indicating a potential upside of 1,782.35%. Given GRI Bio's stronger consensus rating and higher possible upside, analysts clearly believe GRI Bio is more favorable than ObsEva.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
ObsEva	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

GRI Bio has a beta of -1.2, suggesting that its stock price is 220% less volatile than the broader market. Comparatively, ObsEva has a beta of 0.68, suggesting that its stock price is 32% less volatile than the broader market.

Summary

GRI Bio beats ObsEva on 7 of the 12 factors compared between the two stocks.

How does GRI Bio compare to Lexaria Bioscience?

Lexaria Bioscience (NASDAQ:LEXX) and GRI Bio (NASDAQ:GRI) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

13.1% of Lexaria Bioscience shares are owned by institutional investors. Comparatively, 34.0% of GRI Bio shares are owned by institutional investors. 8.4% of Lexaria Bioscience shares are owned by insiders. Comparatively, 8.7% of GRI Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Lexaria Bioscience has higher revenue and earnings than GRI Bio. Lexaria Bioscience is trading at a lower price-to-earnings ratio than GRI Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexaria Bioscience	$710K	12.76	-$11.90M	-$5.10	N/A
GRI Bio	N/A	N/A	-$11.96M	-$74.16	N/A

Lexaria Bioscience currently has a consensus target price of $22.50, indicating a potential upside of 309.84%. GRI Bio has a consensus target price of $32.00, indicating a potential upside of 1,782.35%. Given GRI Bio's higher probable upside, analysts clearly believe GRI Bio is more favorable than Lexaria Bioscience.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexaria Bioscience	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
GRI Bio	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Lexaria Bioscience's return on equity of -174.93% beat GRI Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexaria Bioscience	N/A	-174.93%	-143.89%
GRI Bio	N/A	-199.52%	-143.23%

Lexaria Bioscience has a beta of 0.38, indicating that its stock price is 62% less volatile than the broader market. Comparatively, GRI Bio has a beta of -1.2, indicating that its stock price is 220% less volatile than the broader market.

In the previous week, GRI Bio had 1 more articles in the media than Lexaria Bioscience. MarketBeat recorded 1 mentions for GRI Bio and 0 mentions for Lexaria Bioscience. Lexaria Bioscience's average media sentiment score of 0.00 equaled GRI Bio'saverage media sentiment score.

Company	Overall Sentiment
Lexaria Bioscience	Neutral
GRI Bio	Neutral

Summary

GRI Bio beats Lexaria Bioscience on 6 of the 11 factors compared between the two stocks.

Get GRI Bio News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GRI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GRI vs. The Competition

Export

Metric	GRI Bio	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.60M	$11.81B	$7.01B	$12.98B
Dividend Yield	N/A	2.69%	2.58%	10.06%
P/E Ratio	-0.02	788.51	269.18	24.72
Price / Sales	N/A	743.73	585.57	96.21
Price / Cash	N/A	15.12	28.89	37.42
Price / Book	0.41	10.26	11.40	6.42
Net Income	-$11.96M	$2.77B	$3.45B	$347.03M
7 Day Performance	6.92%	0.82%	1.96%	0.71%
1 Month Performance	-2.30%	-1.63%	-0.55%	-0.87%
1 Year Performance	-94.79%	183.16%	75.51%	21.94%

GRI Bio Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GRI GRI Bio	1.8507 of 5 stars	$1.70 +15.6%	$32.00 +1,782.4%	-95.2%	$2.60M	N/A	N/A	1	Upcoming Earnings Gap Up High Trading Volume
ASBP Aspire Biopharma	0.3102 of 5 stars	$7.04 -2.6%	N/A	-98.1%	$9.36M	$10K	N/A	N/A	News Coverage Gap Up
QNRX Quoin Pharmaceuticals	0.8323 of 5 stars	$4.35 -2.2%	N/A	-24.6%	$8.94M	N/A	N/A	4
CNSP CNS Pharmaceuticals	3.2214 of 5 stars	$5.36 -7.4%	$20.00 +273.1%	-23.4%	$8.46M	N/A	N/A	5	Upcoming Earnings Gap Down
OBSV ObsEva	N/A	N/A	N/A	N/A	$7.94M	N/A	N/A	50

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GRI) was last updated on 8/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

GRI Bio (GRI) Competitors

GRI vs. ASBP, QNRX, CNSP, OBSV, and LEXX

How does GRI Bio compare to Aspire Biopharma?

Summary

How does GRI Bio compare to Quoin Pharmaceuticals?

Summary

How does GRI Bio compare to CNS Pharmaceuticals?

Summary

How does GRI Bio compare to ObsEva?

Summary

How does GRI Bio compare to Lexaria Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

GRI Bio (GRI) Competitors

GRI vs. ASBP, QNRX, CNSP, OBSV, and LEXX

How does GRI Bio compare to Aspire Biopharma?

Which has more volatility and risk, GRI or ASBP?

Do analysts prefer GRI or ASBP?

Do institutionals & insiders hold more shares of GRI or ASBP?

Does the media refer more to GRI or ASBP?

Is GRI or ASBP more profitable?

Which has stronger valuation & earnings, GRI or ASBP?

Summary

How does GRI Bio compare to Quoin Pharmaceuticals?

Which has higher earnings and valuation, GRI or QNRX?

Which has more risk & volatility, GRI or QNRX?

Do analysts rate GRI or QNRX?

Is GRI or QNRX more profitable?

Do insiders and institutionals have more ownership in GRI or QNRX?

Does the media favor GRI or QNRX?

Summary

How does GRI Bio compare to CNS Pharmaceuticals?

Which has more volatility and risk, GRI or CNSP?

Does the media favor GRI or CNSP?

Do insiders and institutionals have more ownership in GRI or CNSP?

Is GRI or CNSP more profitable?

Which has preferable earnings and valuation, GRI or CNSP?

Do analysts recommend GRI or CNSP?

Summary

How does GRI Bio compare to ObsEva?

Do insiders and institutionals have more ownership in GRI or OBSV?

Does the media prefer GRI or OBSV?

Which has better valuation & earnings, GRI or OBSV?

Is GRI or OBSV more profitable?

Do analysts prefer GRI or OBSV?

Which has more risk and volatility, GRI or OBSV?

Summary

How does GRI Bio compare to Lexaria Bioscience?

Do institutionals and insiders have more ownership in LEXX or GRI?

Which has stronger valuation & earnings, LEXX or GRI?

Do analysts recommend LEXX or GRI?

Is LEXX or GRI more profitable?

Which has more volatility and risk, LEXX or GRI?

Does the media refer more to LEXX or GRI?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GRI vs. The Competition

GRI Bio Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools